Jounce Therapeutics
1030 Massachusetts Avenue
Cambridge
Massachusetts
02138
United States
Tel: 857-259-3840
Fax: 617-812-5345
Website: http://www.jouncetx.com/
About Jounce Therapeutics
Jounce Therapeutics is focused on the discovery and development of novel cancer immunotherapies designed to work not by treating a patient's tumor directly, but instead by harnessing the patient's immune system to seek out and attack cancerous cells and tumors.
This transformational approach has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life.
Jounce is building upon the unparalleled expertise of its renowned scientific founders – world leaders in the fields of immunology, cancer biology and clinical and translational medicine in cancer – and its increasing understanding of how cancer cells communicate and interact with the immune system to position the company at the forefront of cancer immunotherapy drug discovery and development.
Based in Cambridge, Mass., Jounce is a private company launched in 2013 with $47 million in Series A venture capital financing by Third Rock Ventures.
126 articles with Jounce Therapeutics
-
Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer
3/16/2023
Jounce Therapeutics, Inc. (Nasdaq: JNCE) today announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer are experiencing deep and durable responses based on a pre-planned informal data review.
-
Jounce Therapeutics has received an unsolicited and non-binding acquisition proposal from Concentra Biosciences, looking to buy 100% of Jounce's equity at a per-share price of $1.80 in cash.
-
One day after revealing a restructuring initiative, Jounce Therapeutics announced it plans to merge its business in an all-stock deal with clinical-stage biotech Redx Pharma.
-
Redx and Jounce Announce Recommended Business Combination
2/23/2023
Redx Pharma and Jounce Therapeutics, Inc. announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction.
-
Jounce Therapeutics Announces Restructuring - February 22, 2023
2/22/2023
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that it is reducing its workforce by approximately 57 percent.
-
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
12/27/2022
Gilead Sciences, Inc. and Jounce Therapeutics, Inc. amended their existing license agreement for GS-1811, enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020.
-
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress
12/8/2022
Jounce Therapeutics, Inc. today reported new clinical data from the INNATE trial with JTX-8064 and pimi and the SELECT trial with vopra and pimi in two poster presentations at the ESMO-IO 2022 Annual Congress being held in Geneva, Switzerland.
-
Jounce Therapeutics Reports Third Quarter 2022 Financial Results
11/10/2022
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
-
Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.
11/2/2022
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today earning a $15.0 million clinical milestone payment from Gilead Sciences, Inc. (NASDAQ: GILD) under the exclusive license agreement for GS-1811, an anti-CCR8 antibody for which Gilead has exclusive rights to develop and commercialize.
-
Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022
10/27/2022
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022.
-
Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress
10/20/2022
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced poster presentations to be made at upcoming medical meetings.
-
Jounce Therapeutics to Participate in the Upcoming September 2022 Investor Conferences
9/7/2022
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that company management will participate in the following upcoming investor conferences in September.
-
Jounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected Patients
8/30/2022
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported top line data from the randomized Phase 2 SELECT trial evaluating vopratelimab (vopra).
-
Jounce Therapeutics announced that a Phase II trial assessing a combination treatment for non-small cell lung cancer failed to meet its primary endpoint.
-
Jounce Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022
7/28/2022
Jounce Therapeutics, Inc. today announced that it will report second quarter 2022 financial results and provide a corporate update on Thursday, August 4, 2022.
-
Jounce Therapeutics to Present at Upcoming Investor Conferences - May 17, 2022
5/17/2022
Jounce Therapeutics, Inc. announced that Jounce management will participate at the following upcoming investor conferences:
-
Jounce Therapeutics Reports First Quarter 2022 Financial Results
5/5/2022
Jounce Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022
4/28/2022
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2022 financial results and provide a corporate update on Thursday, May 5, 2022.
-
Jounce Therapeutics to Participate in Raymond James LILRB/ILT Symposium: Deep Dive into “Myeloid Checkpoint” Therapeutics in Cancer
4/20/2022
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Raymond James LILRB/ILT Symposium: Deep Dive into “Myeloid Checkpoint” Therapeutics.
-
Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
3/2/2022
Jounce Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.